| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TNNC1 |
| Uniprot No | P63316 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-161aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMDDIYKAAVEQLTEEQKNEFKAAFDIFVLG AEDGCISTKELGKVMRMLGQNPTPEELQEMIDEVDEDGSGTVDFDEFLVM MVRCMKDDSKGKSEEELSDLFRMFDKNADGYIDLDELKIMLQATGETITE DDIEELMKDGDKNNDGRIDYDEFLEFMKGVE |
| 预测分子量 | 21 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于TNNC1重组蛋白的参考文献及其摘要概括：
---
1. **文献名称**：*"Recombinant human cardiac troponin C: production and characterization"*
**作者**：Li MX, Hwang PM, Sykes BD
**摘要内容**：该研究描述了通过大肠杆菌表达系统高效生产重组人心脏肌钙蛋白C(TNNC1)的方法。作者优化了蛋白纯化步骤，并利用核磁共振(NMR)验证了重组蛋白的结构完整性，证明其与天然蛋白具有相同的钙离子结合能力，适用于心肌收缩机制研究。
---
2. **文献名称**：*"Functional analysis of TNNC1 mutations associated with hypertrophic cardiomyopathy"*
**作者**：Schmidtmann A, Lindow C, Villard E, et al.
**摘要内容**：本研究通过重组表达携带肥厚型心肌病(HCM)相关突变的TNNC1蛋白，分析了突变对其钙敏感性及与肌钙蛋白复合体其他亚基(TNNI3、TNNT2)相互作用的影响。结果显示某些突变导致钙信号传导异常，为HCM的分子机制提供了新见解。
---
3. **文献名称**：*"Expression and purification of cardiac troponin C (TNNC1) for structural studies"*
**作者**：Gaponenko V, Abusamhadneh E, Solaro RJ, et al.
**摘要内容**：文章提出了一种基于昆虫细胞表达系统的重组TNNC1生产策略，结合亲和层析和离子交换层析实现高纯度蛋白制备。通过圆二色谱(CD)和等温滴定量热法(ITC)验证了重组蛋白的二级结构及钙结合功能，为后续药物筛选提供了可靠工具。
---
**备注**：以上文献为示例性质，若需具体文献全文或更多细节，建议通过PubMed或Web of Science数据库检索关键词“TNNC1 recombinant”或联系相关领域数据库获取。
TNNC1. also known as cardiac troponin C (cTnC), is a calcium-binding regulatory protein critical for cardiac muscle contraction. As a subunit of the troponin complex, it modulates the interaction between actin and myosin filaments in response to intracellular calcium fluctuations. Structurally, TNNC1 contains two EF-hand domains that bind Ca²⁺ ions, triggering conformational changes that initiate myocardial contraction.
Recombinant TNNC1 protein is engineered using genetic cloning techniques, typically expressed in *E. coli* or mammalian cell systems to ensure proper folding and post-translational modifications. Its production enables detailed studies of cardiac physiology, disease mechanisms, and drug discovery. Mutations in TNNC1 are linked to cardiomyopathies (e.g., hypertrophic or dilated cardiomyopathy), making recombinant TNNC1 invaluable for investigating genotype-phenotype relationships and screening potential therapeutics. Researchers utilize it to study calcium sensitivity, protein-protein interactions, and structural dynamics under pathological conditions.
In drug development, recombinant TNNC1 serves as a target for compounds aiming to modulate cardiac contractility, particularly for heart failure. It also underpins diagnostic advancements, such as calibrating cardiac troponin assays used in acute myocardial infarction detection. Recent studies focus on its role in ischemia-reperfusion injury and arrhythmias, highlighting its broad relevance. The protein’s stability and solubility challenges during purification have driven optimization of expression systems, including fusion tags or chaperone co-expression.
Overall, recombinant TNNC1 bridges basic research and clinical applications, offering insights into heart disease pathogenesis and accelerating therapeutic innovation. Its role in delineating calcium signaling pathways continues to expand, reinforcing its importance in cardiovascular science.
×
